A significantly higher proportion of patients with isolated anti-Ro52 antibodies were diagnosed with IM and malignancies, and were also more likely to suffer from ILD and PAH compared with the patients with only isolated anti-Ro60 antibodies or those with both anti-Ro60 and anti-Ro52 antibodies. This evidence concerns the gene RO60 and interstitial lung disease.